InvestorsHub Logo
Followers 164
Posts 9618
Boards Moderated 7
Alias Born 11/06/2005

Re: None

Tuesday, 02/20/2007 9:13:59 AM

Tuesday, February 20, 2007 9:13:59 AM

Post# of 527
Nanogen to Host Fourth Quarter Conference Call and Webcast on February 20, 2007

Monday February 19, 8:00 am ET

SAN DIEGO--(BUSINESS WIRE)--Nanogen, Inc. (Nasdaq:NGEN - News), developer of advanced diagnostic products, will host a conference call on Tuesday, February 20, 2007 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2006 fourth quarter financial results. The financial results press release will be issued at close of market on February 20. Interested investors and others may participate in the conference call by dialing 877-407-9205 for US/Canada participants and 201-689-8054 for international participants.


Audio of management's presentation will be available via live webcast on the investor relations section of Nanogen's corporate website at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on February 20, and can be accessed via telephone at 877-660-6853 for US/Canada participants and (201) 612-7415 for international participants. The account number, 286, along with the conference ID, 231215, will be required to listen to the playback.

About Nanogen, Inc.

Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen's website at www.nanogen.com.

Nanogen Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.



Contact:
Nanogen, Inc.
Robert Saltmarsh, Chief Financial Officer, 858-410-4600
or
Suzanne Clancy, Corporate Communications, 858-410-4688
sclancy@nanogen.com
or
Porter Novelli Life Sciences
Kim Richards, Media & Investor Relations, 619-849-5377
krichards@pnlifesciences.com

--------------------------------------------------------------------------------
Source: Nanogen, Inc.

Check out the Millionaire Players Club

http://investorshub.advfn.com/boards/board.asp?board_id=5414

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.